Blog Archive
-
▼
2007
(90)
-
▼
November
(14)
- Vectura and Sosei, Phase II Studies of QVA149 for ...
- Aeolus Pharmaceuticals, Pipeline, COPD
- Amira Pharmaceuticals, Initiates Clinical Studies ...
- NicOx, TOPIGEN initiates phase 2 proof of concept ...
- SPO Medical, New Oximetry Devices for European Mar...
- Advanced Life Sciences, Cethromycin, Second Pivota...
- Pharmion's Amrubicin, Results Compared to Standard...
- MAP Pharmaceuticals, Phase 2a Clinical Trial of Co...
- Gilead and LG Life Sciences, Global License Agreem...
- Æterna Zentaris, Multi-Center Phase 2 Trial with P...
- Alfacell's ONCONASE, Radiation Sensitizer for Lung...
- Nabi Biopharmaceuticals, NicVAX(R) , Significant R...
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Theravance, Initiation of Phase 2 Clinical Program...
-
▼
November
(14)
Nov 22, 2007
NicOx, TOPIGEN initiates phase 2 proof of concept study in COPD for TPI 1020
November 20, 2007 - ...This new clinical study follows the recent announcement of promising top-line results from a phase 2a study in asthmatic smokers, where TPI 1020 showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects which could be potentially beneficial in COPD (see press release of September 11, 2007). COPD is a respiratory disease caused by chronic inflammation of the lungs and bronchi and represents the third-leading cause of death in the United States... [PDF] NicOx' Press Release - PDF en Français - [PDF] Topigen's Press Release -
Libellés :
Asthma,
Chronic Obstructive Pulmonary Disease (COPD),
NicOx,
Topigen